Real-world effectiveness and tolerability of fixed dose netarsudil/latanoprost in the management of patients with uncontrolled glaucoma
Abstract
This prospective cohort study evaluates the real-world effectiveness and tolerability of the fixed-dose combination of Netarsudil 0.02%/Latanoprost 0.005% in patients with uncontrolled glaucoma. Following sample size determination, patients with any type of uncontrolled glaucoma were consecutively enrolled. Seventy-one eyes from forty patients (mean age 74.7 ± 10.0 years) were included. The median baseline IOP was 18.00 mmHg [IQR: 10], with an average of 2.76 ± 1.10 glaucoma medications. A statistically significant reduction in IOP was observed at each follow-up: 14.00 mmHg [IQR: 6.50] at 1 month ( p < 0.001), 13.00 mmHg [IQR: 8] at 3 months ( p < 0.001), and 13.50 mmHg [IQR: 7.75] at 6 months ( p < 0.001). Subgroup analysis revealed significant IOP reductions in patients with primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). Adverse events were reported in 52.1% of treated eyes, most commonly worsening of conjunctival hyperemia (36.6%). Treatment discontinuation due to adverse events and inadequate IOP control occurred in 15.5% of eyes, respectively. Overall, the Netarsudil 0.02%/Latanoprost 0.005% combination demonstrated meaningful IOP reduction and a manageable safety profile in a real-world clinical setting, even in patients receiving maximally tolerated medical therapy. These findings suggest it may offer an alternative for patients who are not candidates or unwilling for surgical intervention.
Related
- Recurrent delayed hyphema following latanoprost/netarsudil initiation in an eye with a XEN 63 gel stent: a case report.
- Twelve-Month Efficacy and Tolerability of Netarsudil 0.02% in Korean Patients with Primary Open-Angle Glaucoma and Normal-Tension Glaucoma: A Single-Center Retrospective Study.
- Rethinking nasopharyngeal carcinoma management: toward a low-toxicity, highly effective regimen with favorable tolerability and quality of life
- A Poly‐L‐Lactic Acid Formulation for Nasolabial Fold Correction: Handling, Tolerability and Effectiveness in a Prospective Observational Study
- Prevalence, clinical features and emergency department blood pressure management of hypertensive emergencies and uncontrolled hypertension: a retrospective multi-centre study
BibTeX
@article{siligato2026realworld,
title = {{Real-world effectiveness and tolerability of fixed dose netarsudil/latanoprost in the management of patients with uncontrolled glaucoma}},
author = {Alessandro Siligato and Claudia Nardi and Sara Bochicchio and Angelica Dipinto and Mariano Cozzi and Giovanni Staurenghi},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73600-w},
url = {https://www.nature.com/articles/s41598-026-73600-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world effectiveness and tolerability of fixed dose netarsudil/latanoprost in the management of patients with uncontrolled glaucoma
AU - Alessandro Siligato
AU - Claudia Nardi
AU - Sara Bochicchio
AU - Angelica Dipinto
AU - Mariano Cozzi
AU - Giovanni Staurenghi
PY - 2026
DA - 2026/10/08
JO - Scientific Reports
DO - 10.1038/s41598-026-73600-w
UR - https://www.nature.com/articles/s41598-026-73600-w
AB - This prospective cohort study evaluates the real-world effectiveness and tolerability of the fixed-dose combination of Netarsudil 0.02%/Latanoprost 0.005% in patients with uncontrolled glaucoma. Following sample size determination, patients with any type of uncontrolled glaucoma were consecutively enrolled. Seventy-one eyes from forty patients (mean age 74.7 ± 10.0 years) were included. The median baseline IOP was 18.00 mmHg [IQR: 10], with an average of 2.76 ± 1.10 glaucoma medications. A statistically significant reduction in IOP was observed at each follow-up: 14.00 mmHg [IQR: 6.50] at 1 month ( p < 0.001), 13.00 mmHg [IQR: 8] at 3 months ( p < 0.001), and 13.50 mmHg [IQR: 7.75] at 6 months ( p < 0.001). Subgroup analysis revealed significant IOP reductions in patients with primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). Adverse events were reported in 52.1% of treated eyes, most commonly worsening of conjunctival hyperemia (36.6%). Treatment discontinuation due to adverse events and inadequate IOP control occurred in 15.5% of eyes, respectively. Overall, the Netarsudil 0.02%/Latanoprost 0.005% combination demonstrated meaningful IOP reduction and a manageable safety profile in a real-world clinical setting, even in patients receiving maximally tolerated medical therapy. These findings suggest it may offer an alternative for patients who are not candidates or unwilling for surgical intervention.
SN - 2045-2322
ER -